Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
1999 1
2005 1
2008 1
2010 3
2011 1
2012 1
2017 1
2018 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT. Sullivan RJ, et al. Among authors: decrescenzo ga. Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15. Cancer Discov. 2018. PMID: 29247021 Free article. Clinical Trial.
Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.
Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP. Kolodziej SA, et al. Among authors: decrescenzo ga. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3557-60. doi: 10.1016/j.bmcl.2010.04.130. Epub 2010 May 23. Bioorg Med Chem Lett. 2010. PMID: 20529684
Physiochemical drug properties associated with in vivo toxicological outcomes.
Hughes JD, Blagg J, Price DA, Bailey S, Decrescenzo GA, Devraj RV, Ellsworth E, Fobian YM, Gibbs ME, Gilles RW, Greene N, Huang E, Krieger-Burke T, Loesel J, Wager T, Whiteley L, Zhang Y. Hughes JD, et al. Among authors: decrescenzo ga. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4872-5. doi: 10.1016/j.bmcl.2008.07.071. Epub 2008 Jul 24. Bioorg Med Chem Lett. 2008. PMID: 18691886
Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.
Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J. Becker DP, et al. Among authors: decrescenzo ga. J Med Chem. 2010 Sep 23;53(18):6653-80. doi: 10.1021/jm100669j. J Med Chem. 2010. PMID: 20726512
MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.
Kolodziej SA, Hockerman SL, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Stehle N, Swearingen C, Becker DP. Kolodziej SA, et al. Among authors: decrescenzo ga. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3561-4. doi: 10.1016/j.bmcl.2010.04.111. Epub 2010 Apr 28. Bioorg Med Chem Lett. 2010. PMID: 20529685
Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy.
Becker DP, Villamil CI, Barta TE, Bedell LJ, Boehm TL, Decrescenzo GA, Freskos JN, Getman DP, Hockerman S, Heintz R, Howard SC, Li MH, McDonald JJ, Carron CP, Funckes-Shippy CL, Mehta PP, Munie GE, Swearingen CA. Becker DP, et al. Among authors: decrescenzo ga. J Med Chem. 2005 Oct 20;48(21):6713-30. doi: 10.1021/jm0500875. J Med Chem. 2005. PMID: 16220987